15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering DarioHealth Corp, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $10.00 to $11.00, so the covering firms are broadly aligned. The average target of $10.50 sits 38% above the current $7.60. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.63 next quarter toward $-0.68 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to DarioHealth Corp.
As of Jul, 1 of 2 firms rate DRIO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DRIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.63
Range $-0.63 – $-0.62 · 2 analysts · -72% YoY
Next period, 2 analysts expect DarioHealth Corp to earn $-0.63 a share (range $-0.63 – $-0.62), versus $-2.22 a year earlier. Full-year consensus is $-2.81, growing to $-0.68 the year after.
REVENUE · NEXT QUARTER
$6.4M
Range $6.4M – $6.4M · 2 analysts · +29% YoY
Revenue is expected to reach $6.4M (range $6.4M – $6.4M), +28.7% year-over-year. Full-year consensus is $26.3M, rising to $38.8M next year.
Top analysts covering DarioHealth Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DRIO.
#1
David Grossman
Stifel
Buy
$10.00+31.6% to target
Coverage
—
+ Follow
#2
Charles Rhyee
TD Cowen
Hold
$11.00+44.7% to target
Coverage
—
+ Follow
#3
TO
Theodore O'Neill
Litchfield Hills
Buy
$3.00-60.5% to target
Coverage
—
+ Follow
DRIO stock forecast FAQ
What is DRIO's average 12-month price target?+
The 2 analysts with a live target average $10.50 for DarioHealth Corp over the next 12 months, ranging from a $11.00 high to a $10.00 low.
Is DRIO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for DRIO?+
The Street-high target is $11.00 (TD Cowen), and the Street-low is $10.00 (Stifel). The average of all 2 active targets is $10.50.
How many Wall Street analysts cover DRIO?+
2 analysts have an active rating on DarioHealth Corp, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering DRIO?+
Among analysts who currently cover DRIO, David Grossman of Stifel has the strongest overall Quantellect track record. Their current call is Buy with a $10.00 target.
What is DarioHealth Corp's projected EPS for next quarter?+
The consensus estimate is $-0.63 per share (range $-0.63 – $-0.62) across 2 analysts. Full-year EPS is projected at $-2.81, rising to $-0.68 the following year.
How much revenue is DarioHealth Corp expected to report next quarter?+
Consensus revenue is $6.4M (range $6.4M – $6.4M). Full-year revenue is projected at $26.3M, growing to $38.8M next year.
Have analysts been upgrading or downgrading DRIO lately?+
As of Jul, 1 of 2 firms rate DRIO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DRIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
